Shore Capital reaffirmed their buy rating on shares of AstraZeneca (LON:AZN) in a research report released on Tuesday, Digital Look reports.
AZN has been the subject of several other reports. Citigroup reaffirmed a buy rating and set a GBX 7,000 ($91.47) price objective on shares of AstraZeneca in a research note on Monday, May 13th. JPMorgan Chase & Co. set a GBX 7,900 ($103.23) target price on AstraZeneca and gave the stock a buy rating in a research report on Thursday, August 15th. Barclays lifted their target price on AstraZeneca from GBX 7,600 ($99.31) to GBX 7,800 ($101.92) and gave the stock an overweight rating in a research report on Friday, August 16th. Bryan, Garnier & Co reiterated a neutral rating on shares of AstraZeneca in a research report on Wednesday, July 3rd. Finally, Credit Suisse Group set a GBX 7,300 ($95.39) target price on AstraZeneca and gave the stock a buy rating in a research report on Friday, July 26th. Three equities research analysts have rated the stock with a sell rating, six have issued a hold rating and ten have issued a buy rating to the company. AstraZeneca has an average rating of Hold and a consensus target price of GBX 6,688.24 ($87.39).
LON AZN opened at GBX 7,313 ($95.56) on Tuesday. The company has a quick ratio of 0.74, a current ratio of 0.95 and a debt-to-equity ratio of 144.48. The company has a fifty day moving average of GBX 6,885.06 and a two-hundred day moving average of GBX 6,283.40. The firm has a market capitalization of $95.94 billion and a price-to-earnings ratio of 42.72. AstraZeneca has a 52 week low of GBX 5,312 ($69.41) and a 52 week high of GBX 7,475.15 ($97.68).
AstraZeneca Company Profile
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
See Also: Stop Order Uses For Individual Investors
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.